KRAS and neoplasm: For instance, the enrichment of high blood monocyte count and low lymphocyte count in the IO non-beneficial group identified by DeePaN indicates that host peripheral immune status may contribute to IO outcomes; the enrichment of mutated KRAS in the IO beneficial subgroup was supported by literature evidence that KRAS mutations correlating with an inflammatory tumor microenvironment and tumor immunogenicity and thus resulting in superior patient response to PD-1/PD-L1 inhibitors in NSCLC51.